Dwijesh Patel, MD
Interventional Cardiology · Raleigh, NCNPI 1700104221
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Shockwave Medical, Inc accounts for 88.4% of it on its own, with 17 other manufacturers making up the rest.
Across 108 payments — averaging $366.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$35K
- Cordis US CORP.$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$912
- Boston Scientific$523
- Inari Medical, Inc.$183
- E.r. Squibb & Sons, L.L.C.$179
- plus $546 from 12 others
Across 14 payments — averaging $28,952 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$403K
- Medalliance LLC$3K
What the payments were for
- Consulting fees$13,05033%
- Speaking & faculty fees$23,20059%
- Travel & lodging$2761%
- Food & beverage$3,0278%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 21 | $34,960 |
| Cordis US CORP. | 2 | $2,250 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 48 | $912 |
| Boston Scientific | 10 | $523 |
| Inari Medical, Inc. | 4 | $183 |
| E.r. Squibb & Sons, L.L.C. | 5 | $179 |
| Abiomed | 2 | $146 |
| Abbott | 4 | $123 |
| Cardiovascular Systems Inc. | 1 | $59 |
| Stryker | 1 | $42 |
| Medtronic | 2 | $37 |
| Terumo Medical Corporation | 2 | $29 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Philips North America LLC | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,553 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 286 | $257,419 |
| Repatha SureclickEvolocumab | 83 | $94,815 |
| EntrestoSacubitril/Valsartan | 93 | $90,078 |
| JardianceEmpagliflozin | 81 | $63,379 |
| XareltoRivaroxaban | 49 | $32,021 |
| BrilintaTicagrelor | 44 | $25,877 |
| VascepaIcosapent Ethyl | 17 | $8,263 |
| ClopidogrelClopidogrel Bisulfate | 852 | $7,537 |
| Metoprolol Succinate | 494 | $4,915 |
| Rosuvastatin Calcium | 324 | $4,404 |
| Atorvastatin Calcium | 415 | $3,930 |
| Ranolazine ErRanolazine | 41 | $2,528 |
| Nebivolol Hcl | 40 | $2,152 |
| Losartan Potassium | 202 | $1,843 |
| Prasugrel Hcl | 21 | $1,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $90,07893 claims |
| Johnson & JohnsonXarelto | $17 | $32,02149 claims |
| AstraZenecaBrilinta | $19 | $25,87744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$1.6M
- Robert JobeRaleigh$191K
- James ZidarRaleigh$57K
- Willis WuRaleigh$56K
- Islam OthmanRaleigh$50K
- Andrew SampsonRaleigh$48K
- Siva KethaRaleigh$19K
- Mohit PasiRaleigh$16K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.